CareDx, Inc. (CDNA) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-04-28

Key Insights

CareDx is acquiring Naveris, Inc. for $160 million in upfront cash consideration with up to $100 million in earn-out payments tied to revenue milestones in 2026-2027, representing a significant strategic expansion of the company's capabilities.
The transaction includes customary closing conditions including HSR antitrust review clearance and a termination date of October 28, 2026, with a $5 million escrow deposit to secure post-closing adjustments, indicating standard deal structure and governance.
CareDx simultaneously released Q1 2026 financial results and an updated corporate presentation on April 28, 2026, suggesting the company is communicating broader strategic positioning alongside the acquisition announcement to investors.

Want the newest filings?

This analysis covers the filing from 2026-04-28. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-16

CareDx, Inc. has entered into a definitive agreement to sell its CareDx AB subsidiary and certain assets related to its kitted laboratory products business to Eurobio Scientific S.A. for $170 million in cash.
The transaction will allow CareDx to focus on its core transplant diagnostics business, while Eurobio will gain access to CareDx's technology and product portfolio in the US, Canada, and Mexico markets.
CareDx also provided preliminary Q1 2026 financial results, indicating strong performance with revenue and profitability metrics exceeding expectations.

Filed: 2026-02-24

CareDx, Inc. has appointed Keith Kennedy as the new Chief Financial Officer and Chief Operating Officer, effective February 26, 2026.
Nathan Smith, the previous CFO, has resigned for personal reasons, and will receive a severance package including a lump-sum cash payment, bonus payout, and accelerated vesting of restricted stock units.
The company reported its financial results for the quarter ended December 31, 2025, though the details were not provided in the 8-K filing.

Other reports for CareDx, Inc.

Insider Trading Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.